Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?
Sarah MoriceGeoffroy DanieauFrançoise RédiniBénédicte Brounais-Le-RoyerFranck VerrecchiaPublished in: Cancers (2020)
Osteosarcoma and Ewing sarcoma are the most prevalent bone pediatric tumors. Despite intensive basic and medical research studies to discover new therapeutics and to improve current treatments, almost 40% of osteosarcoma and Ewing sarcoma patients succumb to the disease. Patients with poor prognosis are related to either the presence of metastases at diagnosis or resistance to chemotherapy. Over the past ten years, considerable interest for the Hippo/YAP signaling pathway has taken place within the cancer research community. This signaling pathway operates at different steps of tumor progression: Primary tumor growth, angiogenesis, epithelial to mesenchymal transition, and metastatic dissemination. This review discusses the current knowledge about the involvement of the Hippo signaling pathway in cancer and specifically in paediatric bone sarcoma progression.
Keyphrases
- signaling pathway
- poor prognosis
- pi k akt
- epithelial mesenchymal transition
- papillary thyroid
- healthcare
- bone mineral density
- long non coding rna
- induced apoptosis
- end stage renal disease
- intensive care unit
- emergency department
- soft tissue
- squamous cell
- small cell lung cancer
- squamous cell carcinoma
- newly diagnosed
- bone regeneration
- ejection fraction
- mental health
- bone loss
- chronic kidney disease
- childhood cancer
- endothelial cells
- prognostic factors
- peritoneal dialysis
- young adults
- radiation therapy
- patient reported outcomes
- oxidative stress
- endoplasmic reticulum stress
- locally advanced